StudyFinder

A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS]

Status: Recruiting

The purpose of the study is to assess if the study treatment, pelacarsen, taken by people with mild or moderate CAVS and elevated lipoprotein(a) can safely help slow the progression of calcific aortic valve stenosis (CAVS). Pelacarsen is a treatment being tested that acts on a particle called Lp(a), which if elevated, may play a role in CAVS.

I'm interested

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• men and women between the ages of 50 and 79
• diagnosis of mild or moderate calcific aortic valve stenosis
Exclusion Criteria:

• ejection fraction (EF) less than 55%
• severe aortic or mitral valve stenosis
• uncontrolled hypertension
• history of cancer
• women who are pregnant or breast feeding
• unable to have an echocardiogram or CT scan
Interventions:

Drug: Matching placebo, Drug: Pelacarsen (TQJ230) 80mg

Conditions:

Heart & Vascular

Keywords:

Clinics and Surgery Center (CSC), elevated LPa, Aortic Stenosis

Study Contact: Michelle Pitt - henni032@umn.edu
Principal Investigator: Daniel Duprez
Phase: PHASE2
IRB Number: STUDY00022219
See this study on ClinicalTrials.gov

Back